Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ReNeuron Chair Iain Ross moves to executive chair as CEO departs

Tue, 03rd Jan 2023 11:21

(Alliance News) - ReNeuron Group PLC on Tuesday said its chief executive officer has left immediately, replaced by an executive chair.

The Bridgend, Wales-based stem cell and exosomes technology company said Catherine Isted stepped down as CEO with immediate effect on Tuesday, prompting the move of Non-Executive Chair Iain Ross to executive chair.

Ross has been on the board since 2021 and will lead a restructuring of the business, ReNeuron said.

It described Ross as an experienced industry executive, having led several successful biotech turnarounds, including recent examples such as Redx Pharma PLC and Silence Therapeutics PLC.

Ross has run the business as chair since February last year with support from then-chief financial officer Isted, after Olav Hellobo resigned as CEO following seven years in the role.

Tuesday's announcement marked Ross' appointment as executive chair, which means he will now run the business without Isted's support, who had been promoted to CEO in August.

Senior Independent Director Barbara Staehelin said: "We would like to thank Catherine for her contribution over the past 17 months, initially as CFO and more recently as CEO, and wish her well in the future. We are excited about the future of the company and are very grateful to Iain for agreeing to lead the company going forward."

ReNeuron said further announcements will be made in due course.

Shares in ReNeuron were up 0.1% to 8.80 pence each in London on Tuesday morning.

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
26 Oct 2021 19:06

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Read more
26 Oct 2021 14:02

ReNeuron enters cancer therapy collaboration with UCL

(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.

Read more
21 Oct 2021 16:40

Director dealings: Reneuron Group non-executive makes share purchase

(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.

Read more
21 Oct 2021 14:07

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:14

ReNeuron treats first Oxford patient as part of expanded study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.

Read more
11 Oct 2021 11:51

ReNeuron upbeat on positive data from Spain collaboration

(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more
11 Oct 2021 11:05

IN BRIEF: ReNeuron gets positive results from exosome drug data

IN BRIEF: ReNeuron gets positive results from exosome drug data

Read more
11 Oct 2021 10:59

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Read more
1 Oct 2021 11:15

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

Read more
1 Oct 2021 10:33

ReNeuron gets approval to restart RP clinical study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.

Read more
9 Sep 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
6 Aug 2021 10:55

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Read more
14 Jul 2021 15:15

IN BRIEF: ReNeuron hires Swiss exec as senior independent director

IN BRIEF: ReNeuron hires Swiss exec as senior independent director

Read more
8 Jul 2021 11:38

TRADING UPDATES: Jet2 swings to loss; Hyve Group sees busiest quarter

TRADING UPDATES: Jet2 swings to loss; Hyve Group sees busiest quarter

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.